Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F24%3A00014616" target="_blank" >RIV/75010330:_____/24:00014616 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S2666776223002119?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2666776223002119?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.lanepe.2023.100792" target="_blank" >10.1016/j.lanepe.2023.100792</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Popis výsledku v původním jazyce

Background Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: pi = pi(rec)rho(rec) + pi(ex)rho(ex) + pi(non)rho(non); pi(rec), pi(ex), and pi(non) represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while rho(rec), rho(ex), and rho(non) represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings The cHCVprevalence in 29 of 30 EU/EEA countries in 2019was 0.50%[95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID.

Název v anglickém jazyce

Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Popis výsledku anglicky

Background Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: pi = pi(rec)rho(rec) + pi(ex)rho(ex) + pi(non)rho(non); pi(rec), pi(ex), and pi(non) represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while rho(rec), rho(ex), and rho(non) represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings The cHCVprevalence in 29 of 30 EU/EEA countries in 2019was 0.50%[95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Lancet Regional Health-Europe

ISSN

2666-7762

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

January

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

12

Strana od-do

100792

Kód UT WoS článku

001158132700001

EID výsledku v databázi Scopus

2-s2.0-85180548657